Total Payments
$129,960
2024 Payments
$13,034
Companies
23
Transactions
122
Medicare Patients
4,711
Medicare Billing
$1.0M
Payment Breakdown by Category
Other$59,125 (45.5%)
Consulting$40,469 (31.1%)
Research$18,246 (14.0%)
Travel$9,725 (7.5%)
Food & Beverage$2,384 (1.8%)
Education$11.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $57,150 | 19 | 44.0% |
| Consulting Fee | $40,469 | 17 | 31.1% |
| Unspecified | $18,246 | 1 | 14.0% |
| Travel and Lodging | $9,725 | 18 | 7.5% |
| Food and Beverage | $2,384 | 63 | 1.8% |
| Honoraria | $1,975 | 3 | 1.5% |
| Education | $11.92 | 1 | 0.0% |
Payments by Type
General
$111,714
121 transactions
Research
$18,246
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Seagen Inc. | $62,335 | 38 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $23,818 | 17 | $0 (2024) |
| Eli Lilly and Company | $18,246 | 1 | $0 (2022) |
| Gilead Sciences, Inc. | $8,423 | 13 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $5,249 | 7 | $0 (2024) |
| PFIZER INC. | $5,190 | 4 | $0 (2024) |
| GENZYME CORPORATION | $1,596 | 1 | $0 (2021) |
| Daiichi Sankyo Inc. | $1,389 | 2 | $0 (2024) |
| MACROGENICS, INC. | $1,375 | 1 | $0 (2022) |
| Genentech USA, Inc. | $1,100 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,034 | 17 | PFIZER INC. ($5,176) |
| 2023 | $29,866 | 22 | Seagen Inc. ($19,890) |
| 2022 | $60,290 | 27 | Seagen Inc. ($35,201) |
| 2021 | $9,532 | 9 | Seagen Inc. ($5,869) |
| 2020 | $6,525 | 5 | AstraZeneca Pharmaceuticals LP ($3,450) |
| 2019 | $4,841 | 15 | AstraZeneca Pharmaceuticals LP ($4,747) |
| 2018 | $5,715 | 17 | AstraZeneca Pharmaceuticals LP ($5,491) |
| 2017 | $155.70 | 10 | Janssen Biotech, Inc. ($76.29) |
All Payment Transactions
122 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,280.00 | General |
| 12/18/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $16.30 | General |
| 12/11/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $125.33 | General |
| Category: Oncology | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $27.84 | General |
| Category: ONCOLOGY | ||||||
| 09/27/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $34.22 | General |
| Category: ONCOLOGY | ||||||
| 09/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: ONCOLOGY | ||||||
| 07/02/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), REBLOZYL, WELIREG | Food and Beverage | In-kind items and services | $23.17 | General |
| Category: ONCOLOGY | ||||||
| 06/11/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $34.39 | General |
| Category: Immunology | ||||||
| 06/02/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $88.67 | General |
| Category: ONC | ||||||
| 04/25/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Consulting Fee | Cash or cash equivalent | $2,362.50 | General |
| Category: Oncology | ||||||
| 04/10/2024 | PFIZER INC. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,200.00 | General |
| Category: Oncology | ||||||
| 04/10/2024 | PFIZER INC. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $850.68 | General |
| Category: Oncology | ||||||
| 04/10/2024 | PFIZER INC. | TUKYSA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Oncology | ||||||
| 04/03/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 03/14/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $33.79 | General |
| Category: ONCOLOGY | ||||||
| 03/14/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: ONCOLOGY | ||||||
| 02/22/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $420.00 | General |
| Category: ONC | ||||||
| 11/14/2023 | Seagen Inc. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,680.00 | General |
| Category: Oncology | ||||||
| 09/13/2023 | Seagen Inc. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,600.00 | General |
| Category: Oncology | ||||||
| 09/13/2023 | Seagen Inc. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $1,012.72 | General |
| Category: Oncology | ||||||
| 08/11/2023 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| 08/01/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.96 | General |
| Category: Hematology | ||||||
| 05/03/2023 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $5,620.00 | General |
| Category: ONC | ||||||
| 05/03/2023 | Seagen Inc. | TUKYSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,200.00 | General |
| Category: Oncology | ||||||
| 05/03/2023 | Seagen Inc. | TUKYSA (Drug) | Travel and Lodging | In-kind items and services | $839.78 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY | Eli Lilly and Company | $18,246 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 42 | 1,694 | 21,899 | $2.2M | $593,813 |
| 2022 | 21 | 995 | 2,555 | $306,934 | $111,534 |
| 2021 | 22 | 984 | 2,685 | $303,414 | $126,926 |
| 2020 | 24 | 1,038 | 5,056 | $485,870 | $197,602 |
Total Patients
4,711
Total Services
32,195
Medicare Billing
$1.0M
Procedure Codes
114
All Medicare Procedures & Services
114 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 11 | 9,000 | $1.1M | $388,975 | 34.3% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 13 | 2,083 | $156,093 | $34,459 | 22.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 82 | 200 | $77,720 | $29,261 | 37.6% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 51 | 229 | $157,094 | $24,896 | 15.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 273 | 369 | $70,965 | $24,830 | 35.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 143 | 217 | $61,936 | $22,552 | 36.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 39 | 39 | $19,723 | $6,877 | 34.9% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 17 | 4,420 | $39,780 | $6,023 | 15.1% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 103 | 545 | $33,790 | $5,641 | 16.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 150 | 680 | $23,800 | $5,175 | 21.7% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 17 | 84 | $28,056 | $4,593 | 16.4% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 79 | 96 | $11,257 | $3,997 | 35.5% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 30 | 159 | $24,168 | $3,785 | 15.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 48 | 73 | $22,192 | $3,712 | 16.7% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 49 | $10,045 | $3,065 | 30.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $8,139 | $2,794 | 34.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 33 | 213 | $22,365 | $2,768 | 12.4% |
| 86300 | Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | Office | 2023 | 22 | 128 | $15,872 | $2,610 | 16.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 24 | 24 | $5,988 | $1,927 | 32.2% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 11 | 62 | $8,742 | $1,767 | 20.2% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 21 | 21 | $3,843 | $1,592 | 41.4% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 29 | 159 | $8,586 | $1,449 | 16.9% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 29 | 195 | $90,090 | $1,161 | 1.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 26 | 99 | $9,207 | $1,119 | 12.1% |
| 83520 | Measurement of substance using immunoassay technique | Office | 2023 | 26 | 66 | $11,946 | $1,117 | 9.3% |
About Dr. Carol Tweed, MD
Dr. Carol Tweed, MD is a Hematology & Oncology healthcare provider based in Annapolis, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649219155.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carol Tweed, MD has received a total of $129,960 in payments from pharmaceutical and medical device companies, with $13,034 received in 2024. These payments were reported across 122 transactions from 23 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($57,150).
As a Medicare-enrolled provider, Tweed has provided services to 4,711 Medicare beneficiaries, totaling 32,195 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 114 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Annapolis, MD
- Active Since 06/06/2006
- Last Updated 12/03/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1649219155
Products in Payments
- TUKYSA (Drug) $67,511
- LYNPARZA (Drug) $10,213
- Trodelvy (Drug) $8,411
- KISQALI (Drug) $5,186
- MARGENZA (Drug) $1,375
- Herceptin (Biological) $1,100
- Oral Paclitaxel (Drug) $600.00
- JEMPERLI (Biological) $95.85
- IMBRUVICA (Drug) $81.52
- Erleada (Drug) $65.86
- DARZALEX (Biological) $62.17
- ZYTIGA (Drug) $58.20
- Fabhalta (Drug) $34.39
- KEYTRUDA (Biological) $33.16
- XTANDI (Drug) $30.07
- QULIPTA (Drug) $29.65
- JADENU (Drug) $28.40
- IMFINZI (Drug) $24.19
- VENCLEXTA (Drug) $23.66
- Lupron (Drug) $22.07
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Annapolis
Arun Bhandari, Md, MD
Hematology & Oncology — Payments: $117,827
Hematology & Oncology $117,827
Dr. Ravin Garg, M.d, M.D
Hematology & Oncology — Payments: $12,567
Hematology & Oncology $12,567
Dr. Peter Graze, M.d, M.D
Hematology & Oncology — Payments: $11,731
Hematology & Oncology $11,731
Dr. Jeanine Werner, M.d, M.D
Hematology & Oncology — Payments: $8,620
Hematology & Oncology $8,620
Dr. Stuart Selonick, M.d, M.D
Hematology & Oncology — Payments: $6,239
Hematology & Oncology $6,239
Dr. Benjamin Bridges, Md, MD
Hematology & Oncology — Payments: $4,035
Hematology & Oncology $4,035